NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC lessened its stake in NewAmsterdam Pharma (NASDAQ:NAMS) by 1.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 216,493 shares of the company’s stock after selling 4,174 shares during the quarter. Moody Aldrich Partners LLC’s holdings in NewAmsterdam Pharma were worth $3,594,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in NAMS. Jennison Associates LLC purchased a new position in NewAmsterdam Pharma in the first quarter valued at approximately $22,015,000. Artal Group S.A. acquired a new stake in shares of NewAmsterdam Pharma in the first quarter worth $18,920,000. Janus Henderson Group PLC purchased a new position in shares of NewAmsterdam Pharma in the 1st quarter valued at $15,018,000. Decheng Capital LLC acquired a new position in shares of NewAmsterdam Pharma during the 2nd quarter valued at $7,684,000. Finally, TimesSquare Capital Management LLC acquired a new position in shares of NewAmsterdam Pharma during the first quarter worth about $5,407,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Price Performance

Shares of NAMS traded up $0.62 during midday trading on Thursday, hitting $19.92. The company had a trading volume of 63,385 shares, compared to its average volume of 253,528. The company’s 50 day moving average price is $16.91 and its 200 day moving average price is $18.52. NewAmsterdam Pharma has a 52 week low of $5.63 and a 52 week high of $26.35.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.08. The firm had revenue of $2.28 million during the quarter, compared to the consensus estimate of $2.20 million. Equities analysts expect that NewAmsterdam Pharma will post -2.06 EPS for the current fiscal year.

Insider Activity

In related news, CAO Louise Frederika Kooij sold 45,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 19.50% of the company’s stock.

Analyst Ratings Changes

NAMS has been the topic of several recent research reports. Piper Sandler reissued an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Royal Bank of Canada restated an “outperform” rating and set a $31.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Finally, Needham & Company LLC assumed coverage on NewAmsterdam Pharma in a research note on Wednesday, August 28th. They issued a “buy” rating and a $36.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $33.80.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.